Description
A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anti-cancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis
Formal name: 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-α,α-dimethyl-benzeneacetonitrile
Synonyms: Dactolisib
Molecular weight: 469.5
CAS: 915019-65-7
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|mTOR||Product Type|Biochemicals|Kinase Inhibitors|PI3K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling